In order to have the flexibility to opportunistically allocate excess capital to share repurchases, the company announced that its board of directors has authorized a new share repurchase plan under which the company may repurchase up to $125M of the company’s outstanding common stock.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks announces strategic initiative to optimize Ziihera cash flows
- Zymeworks appoints Scott Platshon as acting chief investment officer
- Zymeworks Stock (ZYME) Soars on Positive Results for Cancer Drug Ziihera, Top Analysts Boost Price Targets
- Zymeworks Stock Upgraded to ‘Buy’ on Promising Phase 3 Trial Results and Financial Prospects
- Zymeworks price target raised to $42 from $30 at Jefferies